ADVERTISEMENT
ADVERTISEMENT

Theranos founder Elizabeth Holmes reportedly asked investors for cash to save the company from a sale or default

In a letter to investors obtained by Buzzfeed News, Theranos founder Elizabeth Holmes explained how Theranos is falling behind on the development milestones it needs to hit.

  • Theranos CEO Elizabeth Holmes is asking her investors for more money to keep the company afloat, according to a letter
  • In a letter sent on Tuesday, Holmes explains how Theranos is falling behind on the development milestones it needs to hit under its agreement with Fortress Investment Group, which provided the blood-testing company with $100 million in funding to get it through 2018.
  • "

Theranos is asking its investors for more money to save it from defaulting on its credit agreement that was meant to get the company through 2018, according to a letter obtained by Buzzfeed News.

In December, Theranos said in a letter to investors that it had raised $100 million in secured debt financing from Fortress Investment Group.

"Based on our present projections, we believe we will have sufficient liquidity through 2018, by which point we hope to have secured regulatory approval for miniLab testing for the Zika virus and begun submissions for additional assays," Theranos CEO Elizabeth Holmeswrote in the investor letter in December.

ADVERTISEMENT

However, it seems Theranos is falling behind in that work.

In a letter to investors on Tuesday obtained by Buzzfeed News, Holmes explains how Theranos is falling behind on the development milestones it needs to hit under its agreement with Fortress.

Development of the Zika test has taken longer than expected, and getting its approval was a contingency to getting more funding from Fortress that had been tranched. By the end of July, Theranos will fall below the $3 million liquidity line it needs to maintain or else it will default on its agreement with Fortress. Should that happen, Fortress can take control of Theranos's assets.

So, Holmes is asking her investors — which have already poured more than $700 million into the company — for more money.

"

ADVERTISEMENT

Theranos has been under fire since October 2015 when The Wall Street Journal published an investigation that called into question the accuracy of its blood test.

The Journal reportedTuesday that the blood-testing company, which wasrecently charged with fraudby the SEC, has laid off another 100 employees. It's the third round oflayoffsin the past two years for the blood-testing company. At one point, the companyhad more than 700 employees.

That brings Theranos' headcount to about 24 employees, The Journal reported.

The company's decision Tuesday to lay off the majority of its staff was a step to cut costs, leaving only "financial, legal and administrative personnel alongside a core technical team," Holmes said in the letter.

Enhance Your Pulse News Experience!

Get rewards worth up to $20 when selected to participate in our exclusive focus group. Your input will help us to make informed decisions that align with your needs and preferences.

I've got feedback!

JOIN OUR PULSE COMMUNITY!

Unblock notifications in browser settings.
ADVERTISEMENT

Eyewitness? Submit your stories now via social or:

Email: eyewitness@pulse.ng

ADVERTISEMENT
ADVERTISEMENT